The Surrey Heartlands Integrated Care System Area Prescribing Committee approve the increased access to THREE switches for existing NICE approved anti-VEGF treatments to optimise response. A Diabetic Macular Oedema (DMO) treatment pathway was also agreed by the APC and is attached for information.
PLEASE NOTE: The most cost-effective anti-VEGF treatment is biosimilar ranibizumab which will be counted as a ‘free switch’ for patients where monthly injections is clinically appropriate.
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the use of faricimab as a treatment option for treating Diabetic Macular Oedema in line with NICE TA799.
Faricimab will be given a RED traffic light status. Prescribing will be by hospital specialists only, in line with NICE TA799.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
